MannKind's inhaled insulin Afrezza hit with US FDA complete response letter
18 March 2010
Katie McQue
Please Login to read the full article.
18 March 2010
Katie McQue
katie.mcque@informa.com
Shares in the US company MannKind dropped by 25% earlier this week as investors reacted to a US FDA complete response letter for its inhaled rapid-acting insulin product Afrezza (formerly Afresa).
The product is awaiting a decision for the treatment of adults with types 1 and 2 diabetes...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Not giving up on Afrezza, MannKind anticipates US FDA meeting to firm up trials
- MannKind leaps 33% on FDA OK for Afrezza trials testing new inhaler
- One large drop for MannKind as Afrezza stretches time and money
- US Capitol Capsule: Obama wants one-stop shop for patents, trade & small biz aid
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
